A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
复制标题
DOI：
10.1002/ptr.5475
复制
发表时间：
2015-11-01
影响因子：
7.2
通讯作者：
Fichna, Jakub
中科院分区：
文献类型：
--
作者：
Chen, Chunqiu;Tao, Chunhua;Fichna, Jakub
我们的目的是评估临床症状腹泻为主的肠易激综合征（IBS-D）接受盐酸小檗碱在随机双盲安慰剂对照临床试验。总的来说，196例IBS-D患者被招募参加这项研究;因此，132例患者随机接受每日400 mg盐酸小檗碱，每日两次或安慰剂治疗8周，随后是4周的洗脱期。在2周的导入期后，每天记录腹泻、腹痛、排便频率的迫切需要和任何不良事件。在给药前和完成治疗后，进行IBS症状评分、抑郁和焦虑量表评分以及IBS生活质量量表（QOL）评估。盐酸小檗碱治疗IBS-D的疗效为腹泻次数减少（P=0.032），腹痛次数减少（P
We aimed to evaluate clinical symptoms in diarrhea predominant irritable bowel syndrome (IBS-D) receiving berberine hydrochloride in a randomized double-blind placebo-controlled clinical trial. Overall, 196 patients with IBS-D were recruited for this study; consequently, 132 patients randomized to receive daily 400mg of berberine hydrochloride, delivered twice daily or placebo for 8weeks followed by a 4-week washout period. After a 2-week run-in period, diarrhea, abdominal pain, urgent need for defecation frequency and any adverse events were recorded daily. Prior to administration of the medication and after completing the treatment, assessment of IBS symptom scores, depression and anxiety scale scores and the IBS scale for quality of life (QOL) was carried out. The effects of berberine hydrochloride on IBS-D, defined by a reduction of diarrhea frequency (P=0.032), abdominal pain frequency (P